Amicus is scheduled to resume trading at 11:10 am ET, with quoting to resume at 11:05 am ET, according to Nasdaq. Shares were halted, pending news, before the company announced that the U.S. Food and Drug Administration has approved Pombiliti + Opfolda 65mg capsules for adults living with late-onset Pompe disease who are not improving on their current enzyme replacement therapy, or ERT.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on FOLD:
- Amicus Therapeutics Announces FDA Approval and Launch of New Treatment for Pompe Disease
- Amicus trading halted, news pending
- Amicus Therapeutics to Present at Upcoming Investor Conferences in September 2023
- Amicus Therapeutics Announces Presentation and Posters at the SSIEM Annual Symposium 2023
- Amicus Therapeutics appoints Harford as CFO